On Monday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) opened higher 3.18% from the last session, before settling in for the closing price of $8.49. Price fluctuations for DNA have ranged from $5.26 to $75.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 104.75% over the last five years. Company’s average yearly earnings per share was noted 41.34% at the time writing. With a float of $35.43 million, this company’s outstanding shares have now reached $38.13 million.
The firm has a total of 1218 workers. Let’s measure their productivity. In terms of profitability, gross margin is 58.77%, operating margin of -406.93%, and the pretax margin is -486.98%.
Ginkgo Bioworks Holdings Inc (DNA) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ginkgo Bioworks Holdings Inc is 32.60%, while institutional ownership is 41.54%. The most recent insider transaction that took place on Nov 08 ’24, was worth 822. Before that another transaction happened on Nov 07 ’24, when Company’s Officer proposed sale 99 for $8.39, making the entire transaction worth $831.
Ginkgo Bioworks Holdings Inc (DNA) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -6.4 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -3.43) by -2.97. Wall Street market experts anticipate that the next fiscal year will bring earnings of -2.41 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.34% per share during the next fiscal year.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators
Check out the current performance indicators for Ginkgo Bioworks Holdings Inc (DNA). In the past quarter, the stock posted a quick ratio of 4.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -18.03, a number that is poised to hit -2.73 in the next quarter and is forecasted to reach -7.55 in one year’s time.
Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)
Analysing the last 5-days average volume posted by the [Ginkgo Bioworks Holdings Inc, DNA], we can find that recorded value of 0.82 million was lower than the volume posted last year of 1.12 million. As of the previous 9 days, the stock’s Stochastic %D was 83.55%. Additionally, its Average True Range was 0.59.
During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 26.64%, which indicates a significant decrease from 57.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.26% in the past 14 days, which was lower than the 113.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.65, while its 200-day Moving Average is $24.72. Now, the first resistance to watch is $9.03. This is followed by the second major resistance level at $9.30. The third major resistance level sits at $9.60. If the price goes on to break the first support level at $8.45, it is likely to go to the next support level at $8.15. Should the price break the second support level, the third support level stands at $7.88.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats
There are currently 55,575K shares outstanding in the company with a market cap of 493.24 million. Presently, the company’s annual sales total 251,460 K according to its annual income of -892,870 K. Last quarter, the company’s sales amounted to 56,210 K and its income totaled -217,180 K.
